vTv Therapeutics Inc. (NASDAQ:VTVT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday. The brokerage presently has a $5.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 14.58% from the company’s current price.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

A number of other research firms also recently weighed in on VTVT. Canaccord Genuity restated a “buy” rating on shares of vTv Therapeutics in a research note on Tuesday, February 28th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of vTv Therapeutics in a research note on Thursday, March 30th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $24.00 target price on shares of vTv Therapeutics in a research report on Thursday, March 30th. Five investment analysts have rated the stock with a buy rating, vTv Therapeutics currently has a consensus rating of “Buy” and an average price target of $14.30.

vTv Therapeutics (NASDAQ:VTVT) opened at 4.80 on Friday. vTv Therapeutics has a 12 month low of $4.56 and a 12 month high of $7.50. The stock’s 50 day moving average is $5.01 and its 200-day moving average is $5.46. The firm’s market capitalization is $46.53 million.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.20 million. Equities analysts anticipate that vTv Therapeutics will post ($1.16) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “vTv Therapeutics Inc. (VTVT) Upgraded to “Buy” at Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/06/24/vtv-therapeutics-inc-vtvt-upgraded-to-buy-at-zacks-investment-research.html.

In other vTv Therapeutics news, Director Paul G. Savas bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 31st. The shares were acquired at an average cost of $6.50 per share, for a total transaction of $65,000.00. Following the transaction, the director now directly owns 66,435 shares in the company, valued at $431,827.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of VTVT. Bank of New York Mellon Corp raised its position in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,305 shares during the last quarter. Geode Capital Management LLC raised its position in vTv Therapeutics by 1.8% in the first quarter. Geode Capital Management LLC now owns 37,976 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 676 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in vTv Therapeutics during the first quarter valued at about $261,000. Renaissance Technologies LLC raised its position in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 11,901 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. purchased a new position in vTv Therapeutics during the first quarter valued at about $917,000. Institutional investors and hedge funds own 11.12% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.